Literature DB >> 23143195

Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter].

A Neumann, A Weill, P Ricordeau, J P Fagot, F Alla, H Allemand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23143195     DOI： 10.1007/s00125-012-2769-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  5 in total

1.  Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Authors:  Ronac Mamtani; Kevin Haynes; Warren B Bilker; David J Vaughn; Brian L Strom; Karen Glanz; James D Lewis
Journal:  J Natl Cancer Inst       Date:  2012-08-09       Impact factor: 13.506

2.  Pioglitazone and risk of bladder cancer: clarification of the design of the French study.

Authors:  A T Perez
Journal:  Diabetologia       Date:  2012-11-08       Impact factor: 10.122

3.  Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

Authors:  Isabelle N Colmers; Samantha L Bowker; Sumit R Majumdar; Jeffrey A Johnson
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

4.  Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

Authors:  A Neumann; A Weill; P Ricordeau; J P Fagot; F Alla; H Allemand
Journal:  Diabetologia       Date:  2012-03-31       Impact factor: 10.122

5.  The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.

Authors:  Laurent Azoulay; Hui Yin; Kristian B Filion; Jonathan Assayag; Agnieszka Majdan; Michael N Pollak; Samy Suissa
Journal:  BMJ       Date:  2012-05-30
  5 in total
  5 in total

Review 1.  Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

Authors:  David Della-Morte; Raffaele Palmirotta; Ashish K Rehni; Donatella Pastore; Barbara Capuani; Francesca Pacifici; Maria Laura De Marchis; Kunjan R Dave; Alfonso Bellia; Giuseppe Fogliame; Patrizia Ferroni; Giulia Donadel; Francesco Cacciatore; Pasquale Abete; Chuanhui Dong; Antonello Pileggi; Mario Roselli; Camillo Ricordi; Paolo Sbraccia; Fiorella Guadagni; Tatjana Rundek; Davide Lauro
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

2.  Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.

Authors:  Antoine Pariente; Yohann Mansiaux; Ana Jarné; Francesco Salvo; Cécile Pageot; Julien Bezin; Andy Smith; Bernard Bégaud
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

3.  Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.

Authors:  Min A Lee; Lingchen Tan; Huiseon Yang; Yeong-Gwan Im; Young Jun Im
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

4.  Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.

Authors:  Eugene Han; Suk-Yong Jang; Gyuri Kim; Yong-Ho Lee; Eun Yeong Choe; Chung Mo Nam; Eun Seok Kang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

5.  The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition.

Authors:  Yu Seol Lee; Jeong Su Park; Da Hyun Lee; Dong-Kyu Lee; Sung Won Kwon; Byung-Wan Lee; Soo Han Bae
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-21       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.